ReproCELL Incorporated (4978.T) JPX

Currency In JPY

AD

ReproCELL Incorporated

Address

MetLife Shin-Yokohama Building

Yokohama, 222-0033

Japan

Phone

81 45 475 3887

Sector

Healthcare

Industry

Biotechnology

Employees

96

First IPO Date

June 26, 2013

Key Executives

NameTitlePayYear Born
Chikafumi YokoyamaChief Executive Officer, President & Representative Director01968
Ramakrishna V. ModaliChief Executive Officer of REPROCELL USA Inc.0N/A
Hiroshi YagiAdvisor & Founder0N/A
David BuntonChief Executive officer of REPROCELL Europe0N/A
Daisuke UsuiChief Operating Officer & Director01973
Satoshi MunemuraCFO & GM of Business Administration Dept.0N/A
Hiroyuki MizuguchiAdvisor & Founder0N/A
Stefan A. PrzyborskiCSO of REPROCELL Europe Ltd.0N/A
AD

Description

Established in 2003 and headquartered in Yokohama, Japan, ReproCELL Incorporated operates as a prominent firm specializing in stem cell research. The company furnishes an extensive portfolio of products crucial for various stem cell applications, including a diverse array of specialized reagents for RNA reprogramming, cell growth (such as small molecules, growth factors, and cytokines), cell characterization (like antibodies and staining kits), cell culture (including pluripotent stem cell media and cell substrates), and cell handling (such as cryopreservation media, dissociation solutions, and transfection reagents). Furthermore, ReproCELL provides differentiated induced pluripotent stem cells (iPSCs), related components like feeder cells and induced neurons, 3D cell culture systems, and general laboratory consumables. Complementing its product lines, the company offers a comprehensive suite of services, spanning preclinical genomics, dedicated stem cell research, drug development support (encompassing efficacy, safety, and ADME analyses), access to human tissue samples, therapeutic pipeline development, and a range of clinical services, including laboratory diagnostics and the creation of GMP iPSC master cell banks.

AD